

CLAIMS

1. (original) A bispecific molecule that comprises a first binding domain which binds cell surface membrane-bound heat shock protein (Hsp) and a second binding domain which binds a member of the anti-apoptotic Bcl-2-associated athanogene (Bag) family.
2. (original) The bispecific molecule of claim 1, wherein said Hsp is Hsp70.
3. (currently amended) The bispecific molecule of claim 1 or 2, wherein said Bag is Bag-4.
4. (currently amended) The bispecific molecule of ~~any one of~~ claims 1 to 3, wherein said first binding domain binds to the C-terminal domain of the Hsp and said second binding domain binds to the C-terminal domain of the Hsp and to the C-terminal domain of Bag protein, respectively.
5. (currently amended) The bispecific molecule of ~~any one of~~ claims 1 to 4 that is a bispecific immunoglobulin, wherein the first binding domain is a first immunoglobulin variable region, and the second binding domain is a second immunoglobulin variable region.
6. (currently amended) The bispecific molecule of ~~any one of~~ claims 1 to 5, which is a ~~single chain or a dimeric or multimeric molecule~~.
7. (currently amended) The bispecific molecule of ~~any one of~~ claims 1 to 6, which has at least one further functional domain.
8. (currently amended) The bispecific molecule of ~~any one of~~ claims 1 to 7, which is a bispecific antibody.

9. - 14. (cancelled)

15. (currently amended) ~~The bispecific molecule of claim 7 or 8, or the method of claim 14, wherein said further functional domain is a cytotoxic agent or a label.~~

16. - 20. (cancelled)

21. (currently amended) A method of treating a tumor or infectious disease in a mammal comprising administering to the mammal a therapeutically effective dose of a bispecific molecule of any one of claims 1 to 8, ~~or 15 or 56, 57, or a compound capable of recognizing membrane-bound Bag.~~

22. - 55. (cancelled)

56. (new) The bispecific molecule of claim 4, wherein said first binding domain binds Hsp70 at amino acid residues 454-461 or 450-463.

57. (new) The bispecific molecule of claim 4, wherein said second binding domain binds Bag-4 at amino acid residues 158-457 or 443-457.